JGC
PNT

J. Goldman & Co’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

J. Goldman & Co’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-170,096
Closed -$1.79M – 548
2021
Q1 		$1.79M Buy
+170,096
New +$2.31M 0.06% 250

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

J. Goldman & Co's PNT Position: Q2 2021 in Review

J. Goldman & Co sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2021, closing a stake of 170,096 shares — an estimated $1.79M sold.

J. Goldman & Co first reported a position in PNT in Q1 2021 and held it in 1 quarter. The position peaked at $1.79M in Q1 2021. 21 funds tracked by Wall St. Rank hold PNT as of Q2 2021.

  • J. Goldman & Co reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • J. Goldman & Co sold 170,096 POINT Biopharma Global Inc. Common Stock shares in Q2 2021, an estimated $1.79M.
  • J. Goldman & Co first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • J. Goldman & Co's POINT Biopharma Global Inc. Common Stock position peaked at $1.79M in Q1 2021.
  • 21 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2021.

Based on J. Goldman & Co's 13F filing for Q2 2021, filed 16 Aug 2021.